# A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

> **NCT05940402** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 58 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Emraclidine

## Key facts

- **NCT ID:** NCT05940402
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-24
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940402, "A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05940402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*